INDAZOLE

European patent · EP3183239 · In force

Register entry

Publication number
EP3183239
Application number
EP15744882
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jul 30, 2015
Published
Jun 28, 2017
Granted
Sep 26, 2018
Protection ends at the latest
Jul 29, 2035
Next annual fee due
Jul 31, 2027
IPC classes
C07D 231/56 (2006.01)
C07D 471/04 (2006.01)
A61K 31/416 (2006.01)
A61K 31/437 (2006.01)
A61P 35/00 (2006.01)
Priority
EP 14002929 22.08.2014
PCT application
PCT/EP2015/001570 30.07.2015
PCT publication
WO2016/026549 25.02.2016
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Aug 20, 2026

    Next annual fee due on

    Next annual fee due on
    31.07.2026 → 31.07.2027

    Published in Swissreg on 20.08.2026

  2. Aug 8, 2025

    Next annual fee due on

    Next annual fee due on
    31.07.2025 → 31.07.2026

    Published in Swissreg on 08.08.2025

  3. Aug 20, 2024

    Change

    Published in Swissreg on 20.08.2024

  4. Mar 28, 2024

    Further processing requested

    Published in Swissreg on 28.03.2024

  5. Mar 28, 2024

    Change

    Published in Swissreg on 28.03.2024

  6. Feb 23, 2024

    Deleted, fee unpaid

    Published in Swissreg on 23.02.2024

  7. Aug 1, 2022

    Change

    Published in Swissreg on 01.08.2022

  8. Sep 26, 2018

    Granted

    Published in Swissreg on 26.09.2018

Parties

Holder

Cancer Research Technology Ltd.

Angel Building 407 St. John Street, London EC1V 4AD, GB

Merck Patent GmbH

Frankfurter Strasse 250, 64293 Darmstadt, DE

Inventor

SCHIEMANN, Kai

64342 Seeheim-Jugenheim, DE

MALLINGER, Aurélie

F-54800 Affleville, FR

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.